Sutro Biopharma (STRO) said Friday it has opened enrollment for its registration-directed study of the drug luveltamab tazevibulin in children with a certain type of acute myeloid leukemia.
The trial is global and the majority of the sites are planned to be open by the end of the year, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments